PCSK9 inhibition
Baseline Lp(a) and LDL-C predict greater reduction and arterial stiffness improvement with PCSK9 inhibitors in familial hypercholesterolaemia (Nutr Metab Cardiovasc Dis 2026)
Original title: Impact of baseline LDL-C and Lp(a) levels on PCSK9-targeting therapy efficacy in subjects with familial hypercholesterolemia: real-world data from a tertiary lipid center
This real-world cohort study evaluated 369 genetically confirmed familial hypercholesterolaemia patients treated with PCSK9-targeting therapies for six months. Stratified by baseline LDL-C and Lp(a) medians, participants with higher-than-median baseline lipids showed greater absolute reductions and the most progressive improvement in pulse wave velocity. Concomitantly elevated baseline LDL-C and Lp(a) independently predicted arterial stiffness change (OR: 9.71; 95% CI: 3.14 - 17.85). These observational data indicate that baseline Lp(a) may identify FH patients most likely to derive substantial vascular benefit from PCSK9 inhibition, although residual confounding is inherent to the design.
Original abstract
Background And Aims: Familial hypercholesterolemia (FH) is characterized by elevated LDL-C and increased risk of premature cardiovascular events. PCSK9-targeting therapies reduce LDL-C and Lp(a), with evidence suggesting favorable vascular effects. This study aimed to evaluate the impact of baseline lipid levels on lipid reduction and mechanical vascular improvement after six months of PCSK9-targeting therapies and the association between baseline LDL-C and Lp(a) concentrations and ΔPWV in FH subjects.
Methods And Results: We evaluated lipid profile and PWV at baseline and after six months of PCSK9-targeting therapies in 369 genetically confirmed FH subjects. Study population was divided into four groups based on the combination of baseline LDL-C and Lp(a) values dichotomized at their respective medians. After six months of PCSK9-targeting therapies, greater reductions in LDL-C and Lp(a) were observed in subjects with higher-than-median baseline lipid levels, along with progressive PWV improvement across groups; moreover, logistic regression showed that subjects with concomitantly higher-than-median baseline LDL-C and Lp(a) had the strongest association with ΔPWV (OR: 9.71; 95% CI: 3.14 - 17.85).
Conclusion: FH subjects with higher-than-median baseline LDL-C and Lp(a) showed greater lipid lowering and greater improvements in arterial stiffness after six months add-on PCSK9-targeting therapies; furthermore, higher-than-median baseline LDL-C and Lp(a) had the strongest association with PWV improvement.
epidemiologyfamilial hypercholesterolaemiaPCSK9 inhibitionrisk predictiontherapy
Summary written by lp-a.org from the published abstract; figures as published. Page updated 31 October 2026. Methods.